CARSGEN THERAPEUTICS SHANGHAI CO LTD has a total of 15 patent applications. It increased the IP activity by 300.0%. Its first patent ever was published in 2016. It filed its patents most often in China. Its main competitors in its focus markets biotechnology, pharmaceuticals and measurement are JUNO THERAPEUTICS INC, SBC VIRBAC BIOTECH CO LTD and MOGAM INST BIOMEDICAL RES.
# | Country | Total Patents | |
---|---|---|---|
#1 | China | 15 |
# | Industry | |
---|---|---|
#1 | Biotechnology | |
#2 | Pharmaceuticals | |
#3 | Measurement | |
#4 | Medical technology | |
#5 | Environmental technology |
# | Technology | |
---|---|---|
#1 | Microorganisms | |
#2 | Peptides | |
#3 | Medical preparations | |
#4 | Therapeutic chemical compounds | |
#5 | Analysing materials | |
#6 | Electrotherapy | |
#7 | Climate change adaptation technologies |
# | Name | Total Patents |
---|---|---|
#1 | Li Zonghai | 13 |
#2 | Wang Huamao | 7 |
#3 | Jiang Hua | 5 |
#4 | Wu Xiuqi | 2 |
#5 | Di Shengmeng | 2 |
#6 | Wang Yi | 2 |
#7 | Shi Bizhi | 1 |
#8 | Zhou Min | 1 |
#9 | Luo Hong | 1 |
#10 | Wang Peng | 1 |
Publication | Filing date | Title |
---|---|---|
CN110468105A | Express the protein-bonded immune effector cell of IL-18R | |
CN110438082A | Express the protein-bonded immune effector cell of IL-21R | |
CN109880803A | Chimeric protein, the immune effector cell for expressing chimeric protein and its application | |
CN109503715A | The fusion protein of IL-4R and its application | |
CN109468279A | Target immune effector cell and its application of GPC3 | |
CN109385403A | Target the CAR NK cell of GPC3 | |
CN108866003A | Genetically engineered cell and application |